Fan J - Search Results

1

FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.

Narayan P, Prowell TM, Gao JJ, Fernandes LL, Li E, Jiang X, Qiu J, Fan J, Song P, Yu J, Zhang X, King-Kallimanis BL, Chen W, Ricks TK, Gong Y, Wang X, Windsor K, Rhieu SY, Geiser G, Banerjee A, Chen X, Reyes Turcu F, Chatterjee DK, Pathak A, Seidman J, Ghosh S, Philip R, Goldberg KB, Kluetz PG, Tang S, Amiri-Kordestani L, Theoret MR, Pazdur R, Beaver JA. Narayan P, et al. Among authors: fan j. Clin Cancer Res. 2021 Apr 1;27(7):1842-1849. doi: 10.1158/1078-0432.CCR-20-3652. Epub 2020 Nov 9. Clin Cancer Res. 2021. PMID: 33168657 Free PMC article. Clinical Trial.

2

Using Physiologically Based Pharmacokinetic (PBPK) Modeling to Evaluate the Impact of Pharmaceutical Excipients on Oral Drug Absorption: Sensitivity Analyses.

Chow EC, Talattof A, Tsakalozou E, Fan J, Zhao L, Zhang X. Chow EC, et al. Among authors: fan j. AAPS J. 2016 Nov;18(6):1500-1511. doi: 10.1208/s12248-016-9964-4. Epub 2016 Aug 12. AAPS J. 2016. PMID: 27520379

3

Utility of Physiologically Based Pharmacokinetic Absorption Modeling to Predict the Impact of Salt-to-Base Conversion on Prasugrel HCl Product Bioequivalence in the Presence of Proton Pump Inhibitors.

Fan J, Zhang X, Zhao L. Fan J, et al. AAPS J. 2017 Sep;19(5):1479-1486. doi: 10.1208/s12248-017-0116-2. Epub 2017 Jul 14. AAPS J. 2017. PMID: 28710684

4

A Multiscale Physiologically-Based Pharmacokinetic Model for Doxorubicin to Explore its Mechanisms of Cytotoxicity and Cardiotoxicity in Human Physiological Contexts.

He H, Liu C, Wu Y, Zhang X, Fan J, Cao Y. He H, et al. Among authors: fan j. Pharm Res. 2018 Jul 9;35(9):174. doi: 10.1007/s11095-018-2456-8. Pharm Res. 2018. PMID: 29987398 Free PMC article.

5

Connecting Hydroxychloroquine In Vitro Antiviral Activity to In Vivo Concentration for Prediction of Antiviral Effect: A Critical Step in Treating Patients With Coronavirus Disease 2019.

Fan J, Zhang X, Liu J, Yang Y, Zheng N, Liu Q, Bergman K, Reynolds K, Huang SM, Zhu H, Wang Y. Fan J, et al. Clin Infect Dis. 2020 Dec 15;71(12):3232-3236. doi: 10.1093/cid/ciaa623. Clin Infect Dis. 2020. PMID: 32435791 Free PMC article.

6

FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer.

Shah M, Wedam S, Cheng J, Fiero MH, Xia H, Li F, Fan J, Zhang X, Yu J, Song P, Chen W, Ricks TK, Chen XH, Goldberg KB, Gong Y, Pierce WF, Tang S, Theoret MR, Pazdur R, Amiri-Kordestani L, Beaver JA. Shah M, et al. Among authors: fan j. Clin Cancer Res. 2021 Mar 1;27(5):1220-1226. doi: 10.1158/1078-0432.CCR-20-2701. Epub 2020 Oct 14. Clin Cancer Res. 2021. PMID: 33055172

7

Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018-2019 Submissions to the US FDA's Office of Clinical Pharmacology.

Zhang X, Yang Y, Grimstein M, Fan J, Grillo JA, Huang SM, Zhu H, Wang Y. Zhang X, et al. Among authors: fan j. J Clin Pharmacol. 2020 Oct;60 Suppl 1:S160-S178. doi: 10.1002/jcph.1767. J Clin Pharmacol. 2020. PMID: 33205429

8

Usage of In Vitro Metabolism Data for Drug-Drug Interaction in Physiologically Based Pharmacokinetic Analysis Submissions to the US Food and Drug Administration.

Lee J, Yang Y, Zhang X, Fan J, Grimstein M, Zhu H, Wang Y. Lee J, et al. Among authors: fan j. J Clin Pharmacol. 2021 Jun;61(6):782-788. doi: 10.1002/jcph.1819. Epub 2021 Feb 9. J Clin Pharmacol. 2021. PMID: 33460193

9

FDA Approval Summary: Selumetinib for Plexiform Neurofibroma.

Casey D, Demko S, Sinha A, Mishra-Kalyani PS, Shen YL, Khasar S, Goheer MA, Helms WS, Pan L, Xu Y, Fan J, Leong R, Liu J, Yang Y, Windsor K, Ou M, Stephens O, Oh B, Reaman GH, Nair A, Shord SS, Bhatnagar V, Daniels SR, Sickafuse S, Goldberg KB, Theoret MR, Pazdur R, Singh H. Casey D, et al. Among authors: fan j. Clin Cancer Res. 2021 Aug 1;27(15):4142-4146. doi: 10.1158/1078-0432.CCR-20-5032. Epub 2021 Mar 12. Clin Cancer Res. 2021. PMID: 33712511

10

FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements.

Gandhy SU, Casak SJ, Mushti SL, Cheng J, Subramaniam S, Zhao H, Zhao M, Bi Y, Liu G, Fan J, Adeniyi O, Charlab R, Kufrin D, Thompson MD, Jarrell K, Auth D, Lemery SJ, Pazdur R, Kluetz PG, Fashoyin-Aje LA. Gandhy SU, et al. Among authors: fan j. Clin Cancer Res. 2023 Oct 13;29(20):4027-4031. doi: 10.1158/1078-0432.CCR-23-1042. Clin Cancer Res. 2023. PMID: 37289037 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15,674 results

Search Page

Filters